Clinical trial
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients…
NCT02730299 · Gamida Cell ltd, Industry · Completed
Key facts
| NCT number | NCT02730299 |
|---|---|
| Title | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS |
| Official title | A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies |
| Lead sponsor | Gamida Cell ltd, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia |
| Intervention type | Drug, Other |
| Interventions | NiCord® (omidubicel), Cord Blood Unit |
| Enrollment | 125 |
| Start date | Dec 16, 2016 |
| Primary completion | Apr 29, 2021 |
| Completion | Feb 7, 2025 |
| First posted | Apr 6, 2016 |
| Last update posted | Apr 6, 2025 |
| Countries | Brazil, France, Israel, Italy, Netherlands, Portugal, Singapore, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: